Brief: Cullinan Oncology Announces U.S. FDA Clearance Of Investigational New Drug Application For CLN-617

Cullinan Therapeutics

27/03/2023 12:24

March 27 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES U.S. FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR CLN-617, A NOVEL FUSION
PROTEIN HARNESSING IL-2 AND IL-12 CYTOKINES
    * CULLINAN ONCOLOGY INC - WILL INITIALLY EVALUATE CLN-617 IN
A
PHASE 1 TRIAL IN PATIENTS WITH ADVANCED SOLID TUMORS

Source text for Eikon:  ID:nGNX8HJDSC 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;))